NCT03561740View on ClinicalTrials.gov

A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

PHASE3RecruitingINTERVENTIONAL

Enrollment

794

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

June 15, 2023

Study Completion Date

December 31, 2028

Conditions

Breast Cancer

Interventions

DRUG

capecitabine

additional metronomic chemotherapy of capecitabine

Trial Locations (1)

510060

RECRUITING

Shusen Wang, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER